Patent US4493891A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4493891A Expired / Lapsed US ⏱️ 0.0 years remaining

Determination of oxidized α-1-proteinase inhibitor in serum or plasma

Assignee: University of Georgia Research Foundation Inc
•
Filing: 1982-07-27
•
Granted: 1985-01-15
•
Expires: 2002-07-27
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A new method of determining oxidized alpha -1-proteinase inhibitor in serum or plasma for use in studying the development of chronic obstructive lung disease is disclosed. Levels of oxidized alpha -1-proteinase inhibitor indicate the potential for emphysema development with higher levels showing a decrease in lung protection against elastolytic enzymes such as elastase. This method can be used for patients with a potential for chronic obstructive lung disease rather than having to use bronchial lavage methods for such patients. No other method is known to exist for determining oxidized alpha -1-proteinase inhibitor in serum or plasma.

Inventors

  • 👤 James Travis

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 07:44
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/34; C12Q1/37

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 335 words
A method for determining percent of oxidized α-1-proteinase inhibitor present in an unknown sample of serum or plasma comprising: (a) assaying a first portion of the unknown sample of serum or plasma for enzymatic activity of an enzyme inhibitable by α-1-proteinase inhibitor; (b) assaying a second portion of the unknown sample of serum or plasma for enzymatic activity of an elastase; (c) selecting known standards and determining activity for both the enzyme inhibitable by α-1-proteinase inhibitor and the elastase in said standards; (d) determining an oxidized ratio, K o , of the unknown sample of serum or plasma wherein ##EQU11## wherein T k =Enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor in the standard solution of said enzyme; wherein T u =Enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor of an unknown solution comprising the standard solution of said enzyme and the unknown sample of serum or plasma; wherein E k =Enzymatic activity of the elastase in the standard solution of the elastase; and wherein E u =Enzymatic activity of the elastase of an unknown solution comprising the standard solution of the elastase and the unknown sample of serum or plasma; (e) determining a reduced ratio, K R , of a standard reduced sample of serum or plasma, wherein ##EQU12## wherein T k =Enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor in the standard solution of said enzyme; wherein T r =Enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor in a known solution comprising the standard solution of said enzyme and the standard reduced sample of serum or plasma; wherein E k =Enzymatic activity of the elastase in the standard solution of the elastase; and wherein E r =Enzymatic activity of the elastase in a known solution comprising the standard solution of the elastase and the standard reduced sample of serum or plasma; (f) substituting the reduced ratio and the oxidized ratio into an equation ##EQU13## and solving the equation for X, whereby X is the percent of oxidized α-1-proteinase inhibitor.
Claim 2
Independent Claim 335 words
A method for determining percent of oxidized α-1-proteinase inhibitor present in an unknown sample of serum or plasma comprising: (a) assaying a first portion of the unknown sample of serum or plasma for enzymatic activity of an enzyme inhibitable by α-1-proteinase inhibitor; (b) assaying a second portion of the unknown sample of serum or plasma for enzymatic activity of an elastase; (c) selecting known standards and determining activity for both the enzyme inhibitable by α-1-proteinase inhibitor and the elastase in said standards; (d) determining an oxidized ratio, K o , of the unknown sample of serum or plasma wherein ##EQU11## wherein T k =Enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor in the standard solution of said enzyme; wherein T u =Enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor of an unknown solution comprising the standard solution of said enzyme and the unknown sample of serum or plasma; wherein E k =Enzymatic activity of the elastase in the standard solution of the elastase; and wherein E u =Enzymatic activity of the elastase of an unknown solution comprising the standard solution of the elastase and the unknown sample of serum or plasma; (e) determining a reduced ratio, K R , of a standard reduced sample of serum or plasma, wherein ##EQU12## wherein T k =Enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor in the standard solution of said enzyme; wherein T r =Enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor in a known solution comprising the standard solution of said enzyme and the standard reduced sample of serum or plasma; wherein E k =Enzymatic activity of the elastase in the standard solution of the elastase; and wherein E r =Enzymatic activity of the elastase in a known solution comprising the standard solution of the elastase and the standard reduced sample of serum or plasma; (f) substituting the reduced ratio and the oxidized ratio into an equation ##EQU13## and solving the equation for X, whereby X is the percent of oxidized α-1-proteinase inhibitor.
Claim 3
Dependent Claim 32 words
A method according to claim 1 wherein concentrations of the enzyme inhibitable by α-1-proteinase inhibitor are selected which approximate the concentration of said enzyme in the unknown sample of serum of plasma.
Claim 4
Dependent Claim 25 words
A method according to claim 2 wherein elastase concentrations are selected which approximate the concentration of elastase in the unknown sample of serum or plasma.
Claim 5
Dependent Claim 15 words
A method according to claim 3 wherein the enzyme inhibitable by α-1-proteinase inhibitor is trypsin.
Claim 6
Dependent Claim 48 words
A method according to claim 1, wherein the enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor is measured as the change in absorbance at 253 nanometers per minute and wherein enzymatic activity of the elastase is measured as the change in absorbance at 400 nanometers per minute.
Claim 7
Dependent Claim 19 words
A method according to claim 5 wherein the standard solution of the elastase is prepared with porcine pancreatic elastase.
Claim 8
Dependent Claim 22 words
A method according to claim 6 wherein the standard solution of the enzyme inhibitable by α-1-proteinase inhibitor is prepared with porcine trypsin.
Claim 9
Dependent Claim 22 words
A method according to claim 6 wherein the standard solution of the enzyme inhibitable by α-1-proteinase inhibitor is prepared with bovine α-chymotrypsin.
Claim 10
Dependent Claim 19 words
A method according to claim 7 wherein the standard reduced sample of serum or plasma is reduced by mercaptoethanol.
Claim 11
Dependent Claim 24 words
A method according to claim 9 wherein the enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor is measured using Succinyl-L-alanyl-L-alanyl-L-alanyl-paranitroanilide as a substrate.
Claim 12
Dependent Claim 26 words
A method according to claim 10 wherein the enzymatic activity of the enzyme inhibitable by α-1-proteinase inhibitor is measured using N-benzoyl-L-arginine ethyl ester as a substrate.
Claim 13
Dependent Claim 31 words
A method according to claim 11 wherein the standard solution of the elastase comprises the elastase in 0.05 M Tris, 0.05 M NaCl, pH 8.0, at a concentration of 5 mg/ml.
Claim 14
Dependent Claim 31 words
A method according to claim 11 wherein the standard solution of the enzyme inhibitable by α-1-proteinase inhibitor comprises said enzyme in 10 -3 M HCl at a concentration of 5 mg/ml.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-01-15 1988-07-16 1989-01-15 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-01-15 1992-07-16 1993-01-15 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-01-15 1996-07-16 1997-01-15 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag